Skip to main content
. 2024 Aug 29;134(20):e177384. doi: 10.1172/JCI177384

Figure 4. Characterization of BVax-derived Ig reactivity in patients with GBM.

Figure 4

(A) Schema depicting the protocol for the human IP-MS experiments used to identify tumor-specific antigens recognized by BVax-derived Abs. (B) Heatmap revealing hierarchical clustering of GBM tumor antigens recognized by BVax-derived Igs (n = 3). Targets related to adhesion, motility, or the ECM are shown in red.